Clinical application progress of immune induction regimen for kidney transplantation

He Long; Wang Boqian

doi:10.3969/j.issn.1674-7445.2021.06.006

Volume 12 Issue 6

Nov. 2021

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2021 > 12(6): 682-686

He Long, Wang Boqian. Clinical application progress of immune induction regimen for kidney transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 682-686. doi: 10.3969/j.issn.1674-7445.2021.06.006

Citation:

He Long, Wang Boqian. Clinical application progress of immune induction regimen for kidney transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 682-686. doi: 10.3969/j.issn.1674-7445.2021.06.006

Citation:

He Long, Wang Boqian. Clinical application progress of immune induction regimen for kidney transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 682-686. doi: 10.3969/j.issn.1674-7445.2021.06.006

PDF( 5452 KB)

Clinical application progress of immune induction regimen for kidney transplantation

doi: 10.3969/j.issn.1674-7445.2021.06.006

He Long^,,
Wang Boqian

Organ Transplantation Center, Northern Theater Command General Hospital of Chinese People's Liberation Army, Shenyang 110000, China

More Information

Corresponding author: He Long, Email: helongyh@vip.qq.com
Received Date: 2021-08-18
Publish Date: 2021-11-15

Abstract

Abstract

With the development of immunosuppressants and optimization of immunosuppressive regimens, the survival rates of kidney transplant recipients and grafts have been significantly increased, whereas the incidence of acute rejection and delayed graft function have also been significantly reduced. However, the standard triple immunosuppressive regimen (calcineurin inhibitor+antimetabolite+glucocorticoid) still cannot effectively control the rejection of transplant kidney. Consequently, immune induction before transplantation has been proposed. Immune induction therapy may delay the application time and reduce the dosage of calcineurin inhibitor, lower the incidence of short-term acute rejection after operation, and improve the middle- and long-term prognosis of the recipients. In this article, research progresses on monoclonal antibody-based immune induction regimen, polyclonal antibody-based immune induction regimen and mesenchymal stem cell-based immune induction regime were investigated, aiming to provide reference for optimizing the immune induction regime for kidney transplantation.
- Kidney transplantation,
- Immune induction,
- Immunosuppressant,
- Rituximab,
- Basiliximab,
- Alemtuzumab,
- Antithymocyte globulin,
- Mesenchymal stem cell

FullText(HTML)

References(40)

References

[1]	GOLSHAYAN D, PASCUAL M. Burden of end-stage renal disease and evolving challenges in kidney transplantation[J]. Transpl Int, 2019, 32(9): 889-891. DOI: 10.1111/tri.13490.
[2]	NAGARAJAN M, RAMANATHAN S, DHANAPRIYA J, et al. Impact of acute kidney injury on renal allograft survival[J]. Ren Fail, 2017, 39(1): 40-44. DOI: 10.1080/0886022X.2016.1244076.
[3]	POSNER J, BARRINGTON P, BRIER T, et al. Monoclonal antibodies: past, present and future[J]. Handb Exp Pharmacol, 2019, 260: 81-141. DOI: 10.1007/164_2019_323.
[4]	NELSON PN, REYNOLDS GM, WALDRON EE, et al. Monoclonal antibodies[J]. Mol Pathol, 2000, 53(3): 111- 117. DOI: 10.1136/mp.53.3.111.
[5]	李聪然, 石炳毅, 蔡明, 等. 巴利昔单抗对肾移植排斥反应及移植物存活影响的Meta分析[J]. 解放军医学杂志, 2009, 34(8): 1012-1015. DOI: 10.3321/j.issn:0577-7402.2009.08.025. LI CR, SHI BY, CAI M, et al. Meta-analysis of the effect of basiliximab on renal graft rejection and survival[J]. Med J Chin PLA, 2009, 34(8): 1012-1015. DOI: 10.3321/j.issn:0577-7402.2009.08.025.j.issn:0577-7402.2009.08.025.
[6]	WANG X, DU W, ZHANG X, et al. The influence of different disease states on rituximab pharmacokinetics[J]. Curr Drug Metab, 2020, 21(12): 938-946. DOI: 10.2174/1389200221666200719004035.
[7]	OOMEN I, NASSAR-SHEIKH RASHID A, BOUTS AHM, et al. Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases[J]. Clin Exp Rheumatol, 2021, [Epub ahead of print].
[8]	方佳丽, 陈正, 郭予和, 等. 利妥昔单抗联合ATG作为高致敏肾移植受者免疫诱导方案的安全性及有效性[J]. 中华医学杂志, 2019, 99(16): 1232-1236. DOI: 10.3760/cma.j.issn.0376-2491.2019.16.008. FANG JL, CHEN Z, GUO YH, et al. Clinical efficacy and safety of combined induction therapy with rituximab and ATG in highly sensitized kidney transplant recipients[J]. Nat Med J China, 2019, 99(16): 1232-1236. DOI: 10.3760/cma.j.issn.0376-2491.2019.16.008.
[9]	GENBERG H, HANSSON A, WERNERSON A, et al. Pharmacodynamics of rituximab in kidney transplantation[J]. Transplantation, 2007, 84(12 Suppl): S33-S36. DOI: 10.1097/01.tp.0000296122.19026.0f.
[10]	SINANGIL A, UCAR ZA, KOC Y, et al. Outcome of desensitization therapy in immunologically high-risk kidney transplantation: single-center experience[J]. Transplant Proc, 2019, 51(7): 2268-2273. DOI: 10.1016/j.transproceed.2019.04.068.
[11]	PARAJULI S, MANDELBROT DA, MUTH B, et al. Rituximab and monitoring strategies for late antibodymediated rejection after kidney transplantation[J]. Transplant Direct, 2017, 3(12): e227. DOI: 10.1097/TXD.0000000000000746.
[12]	JOOSTEN I, BAAS MC, KAMBUROVA EG, et al. Anti-B cell therapy with rituximab as induction therapy in renal transplantation[J]. Transpl Immunol, 2014, 31(4): 207-209. DOI: 10.1016/j.trim.2014.09.011.
[13]	FLORESCU DF, SEAMAN JA, KALIL AC, et al. Opportunistic infections after induction with alemtuzumab or basiliximab: a 3-year kidney transplantation experience[J]. Transplant Proc, 2021, 53(3): 1058-1063. DOI: 10.1016/j.transproceed.2020.08.025.
[14]	HANAWAY MJ, WOODLE ES, MULGAONKAR S, et al. Alemtuzumab induction in renal transplantation[J]. N Engl J Med, 2011, 364(20): 1909-1919. DOI: 10.1056/NEJMoa1009546.
[15]	HERTIG A, ZUCKERMANN A. Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: an update[J]. Transpl Immunol, 2015, 32(3): 179-187. DOI: 10.1016/j.trim.2015.04.003.
[16]	DESCOUROUEZ JL, JORGENSON MR, PARAJULI S, et al. Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction[J]. Clin Nephrol, 2020, 93(2): 77-84. DOI: 10.5414/CN109934.
[17]	SABAH TK, KHALID U, ILHAM MA, et al. Induction with ATG in DCD kidney transplantation; efficacy and relation of dose and cell markers on delayed graft function and renal function[J]. Transpl Immunol, 2021, 66: 101388. DOI: 10.1016/j.trim.2021.101388.
[18]	GUIRADO L. Does rabbit antithymocyte globulin (thymoglobuline^®) have a role in avoiding delayed graft function in the modern era of kidney transplantation?[J]. J Transplant, 2018: 4524837. DOI: 10.1155/2018/4524837.
[19]	RUAN V, CZER LS, AWAD M, et al. Use of anti-thymocyte globulin for induction therapy in cardiac transplantation: a review[J]. Transplant Proc, 2017, 49(2): 253-259. DOI: 10.1016/j.transproceed.2016.11.034.
[20]	KOYAWALA N, SILBER JH, ROSENBAUM PR, et al. Comparing outcomes between antibody induction therapies in kidney transplantation[J]. J Am Soc Nephrol, 2017, 28(7): 2188-2200. DOI: 10.1681/ASN.2016070768.
[21]	CREMASCHI L, VON VERSEN R, BENZING T, et al. Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: a health economic analysis from a German perspective[J]. Transpl Int, 2017, 30(10): 1011-1019. DOI: 10.1111/tri.12991.
[22]	LEE KW, PARK JB, CHO CW, et al. The impact of donorspecific anti-human leukocyte antigen (HLA) antibody rebound on the risk of antibody mediated rejection in sensitized kidney transplant recipients[J]. Ann Transplant, 2017, 22: 166-176. DOI: 10.12659/aot.902266.
[23]	QIU J, LI J, CHEN G, et al. Induction therapy with thymoglobulin or interleukin-2 receptor antagonist for Chinese recipients of living donor renal transplantation: a retrospective study[J]. BMC Nephrol, 2019, 20(1): 101. DOI: 10.1186/s12882-019-1293-2.
[24]	ZHANG R. Donor-specific antibodies in kidney transplant recipients[J]. Clin J Am Soc Nephrol, 2018, 13(1): 182-192. DOI: 10.2215/CJN.00700117.
[25]	LEE H, LEE S, JEON JS, et al. Thymoglobulin versus basiliximab induction therapy in low-risk kidney transplant recipients: a single-center experience[J]. Transplant Proc, 2018, 50(5): 1285-1288. DOI: 10.1016/j.transproceed.2018.02.088.
[26]	SAIDI RF, MOGHADASALI R, SHEKARCHIAN S. Utilization of mesenchymal stem cells in kidney transplantation: from bench to bedside[J]. Iran J Kidney Dis, 2019, 13(4): 213-224.
[27]	WANG X, YANG C, HU L, et al. Tolerance induction with donor hematopoietic stem cell infusion in kidney transplantation: a single-center experience in China with a 10-year follow-up[J]. Ann Transl Med, 2020, 8(21): 1378. DOI: 10.21037/atm-20-2502a.
[28]	PERICO N, CASIRAGHI F, TODESCHINI M, et al. Long-term clinical and immunological profile of kidney transplant patients given mesenchymal stromal cell immunotherapy[J]. Front Immunol, 2018, 9: 1359. DOI: 10.3389/fimmu.2018.01359.
[29]	HAFAZEH L, CHANGIZI-ASHTIYANI S, GHASEMI F, et al. Stem cell therapy ameliorates ischemia-reperfusion induced kidney injury after 24 hours reperfusion[J]. Iran J Kidney Dis, 2019, 13(6): 380-388.
[30]	ZILBERMAN-ITSKOVICH S, ABU-HAMAD R, ZARURA R, et al. Human mesenchymal stromal cells ameliorate complement induced inflammatory cascade and improve renal functions in a rat model of ischemiareperfusion induced acute kidney injury[J]. PLoS One, 2019, 14(9): e0222354. DOI: 10.1371/journal.pone.0222354.
[31]	VOLAREVIC V, GAZDIC M, SIMOVIC MARKOVIC B, et al. Mesenchymal stem cell-derived factors: immuno-modulatory effects and therapeutic potential[J]. Biofactors, 2017, 43(5): 633-644. DOI: 10.1002/biof.1374.
[32]	SONG N, SCHOLTEMEIJER M, SHAH K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential[J]. Trends Pharmacol Sci, 2020, 41(9): 653-664. DOI: 10.1016/j.tips.2020.06.009.
[33]	NAJAR M, FAYYAD-KAZAN M, MERIMI M, et al. Mesenchymal stromal cells and natural killer cells: a complex story of love and hate[J]. Curr Stem Cell Res Ther, 2019, 14(1): 14-21. DOI: 10.2174/1574888X13666180912125736.
[34]	GUGJOO MB, HUSSAIN S, AMARPAL, et al. Mesenchymal stem cell-mediated immuno-modulatory and anti- inflammatory mechanisms in immune and allergic disorders[J]. Recent Pat Inflamm Allergy Drug Discov, 2020, 14(1): 3-14. DOI: 10.2174/1872213X14666200130100236.
[35]	DEBOSSCHERE Y, DEPUYDT E, PAUWELYN G, et al. Safety and immunomodulatory properties of equine peripheral blood-derived mesenchymal stem cells in healthy cats[J]. Vet Immunol Immunopathol, 2020, 227: 110083. DOI: 10.1016/j.vetimm.2020.110083.
[36]	王媞尔, 史明霞. 间充质干细胞旁分泌作用的研究进展[J]. 实用医学杂志, 2021, 37(13): 1651-1654. DOI: 10.3969/j.issn.1006-5725.2021.13.001. WANG TE, SHI MX. Research advance in paracrine role of mesenchymal stem cells[J]. J Pract Med, 2021, 37(13): 1651-1654. DOI: 10.3969/j.issn.1006-5725.2021.13.001.
[37]	ZHAO L, HU C, HAN F, et al. Induction therapy with mesenchymal stromal cells in kidney transplantation: a Meta-analysis[J]. Stem Cell Res Ther, 2021, 12(1): 158. DOI: 10.1186/s13287-021-02219-7.
[38]	SANABRIA-DE LA TORRE R, QUIÑONES-VICO MI, FERNÁNDEZ-GONZÁLEZ A, et al. Alloreactive immune response associated to human mesenchymal stromal cells treatment: a systematic review[J]. J Clin Med, 2021, 10(13): 2991. DOI: 10.3390/jcm10132991.
[39]	PERICO N, CASIRAGHI F, INTRONA M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility[J]. Clin J Am Soc Nephrol, 2011, 6(2): 412-422. DOI: 10.2215/CJN.04950610.
[40]	CASIRAGHI F, AZZOLLINI N, TODESCHINI M, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation[J]. Am J Transplant, 2012, 12(9): 2373- 2383. DOI: 10.1111/j.1600-6143.2012.04115.x.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (562) PDF downloads(161)

Clinical application progress of immune induction regimen for kidney transplantation

doi: 10.3969/j.issn.1674-7445.2021.06.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical application progress of immune induction regimen for kidney transplantation

doi: 10.3969/j.issn.1674-7445.2021.06.006

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content